Medina AF, Bedolla GCP, Guerrero SJF

Language: Spanish
References: 18
Page: 227-233
PDF size: 186.67 Kb.

ABSTRACT

Objective: To analyze the association between depression and anxiety with poor glycemic control in patients with type 2 diabetes. Methods: Cohort study, with 188 patients from the DIABETIMSS program in a Family Medicine Unit in Ciudad Madero, Tamaulipas, Mexico. The patients signed the informed consent document. Anthropometric data and laboratory results were obtained and the Hospital Anxiety and Depression Scale was applied at baseline and six months. Results: 188 patients were included, 65.43% were women and 34.57% were men. Age between 27 to 91 years. 43.1% (n=81) of the patients did not suffer from psychological disorders and 56.9% presented some disorder; 15.4% had anxiety, 15.4% had depression, 26.1% had a mixed disorder. The patients had a mean serum glucose of 172.8 mg/dl and a mean HbA1c of 9.19%. After six months, glucose and HbA1c values decreased drastically in patients without psychological disorders and also in patients with mixed disorder; while in the cases in which they presented anxiety there was a slight decrease and in depression, after six months they maintained practically the same levels with HbA1c 9.2% at the beginning and 9.1% in the second measurement. Conclusions: Anxiety and depression are associated with poor glycemic control of diabetes.

REFERENCES

1. Organización Mundial de la Salud. Temas de salud.Informe mundial sobre la Diabetes. [Internet]. (07 demayo de 2017). (Consultado 12 de diciembre 2022).Disponible en: https://www.who.int/diabetes/global-report/es/

2. Mansori, K. Shiravand, N. Association between depressionwith glycemic control and its Complicationsin type 2 diabetes. Diabetes & Metabolic syndrome:Clinical Research & Reviews, 2019;1:1555-1560.

3. Gomes, M. Rathmann, W. Treatment of type 2 diabetesmellitus worldwide: Baseline patient characteristics inthe global discover study. Diabetic research and Clinicalpractice, (2018). Volumen 1. Número 15. Pag. 20-32.

4. Rojas, R. Basto, A. Prevalencia de diabetes por diagnósticomédico previo México. Revista de Salud Públicade México, (2018). Volumen 60. Número 3. Pag.224-232.

5. Basto, A. Barrientos, T. Prevalencia de diabetes y descontrolglucémico en México: Resultados de la Ensanut2016. Revista de Salud Pública de México 2019;62(1):50-59.

6. American Psychological Association. Superando la depresión.[Internet]. (13 de enero de 2017). (consultado12 de diciembre 2022). Disponible en: https://www.apa.org/centrodeapoyo/trastornos-depresivos#

7. Unlenbusch, N. Löwe, B. Depression and anxiety inpatients with different rare chronic diseases: A crosssectional study. Plos ONE, (2019). Volumen 14. Número2. Pag. 1-17.

8. Asuzu, C. Walker, R. Pathways for relationship betweendiabetes distress, depression, fatalism and glycemiccontrol in adults with type 2 diabetes. Journal ofDiabetes and its Complications 2017;1:169-174.

9. Becerra, N. Medina, R. Depresión en pacientescon diabetes mellitus tipo 2 del programa DIABETIMSSen Guadalajara, Jalisco, México. Conamed2019;24(4):174-178.

10. American Psychological Association. Más allá de lapreocupación. [Internet] (10 de octubre de 2017). (consultado10 de diciembre 2022): Disponible en: https://www.apa.org/centrodeapoyo/preocupacion#:~:text=Todos%20sentimos%20preocupaci%C3%B3n%20o%20nerviosismo,con%20el%20paso%20del%20tiempo.

11. Indelicato, L. Dauriz, M. Psychological distress,self- efficacy and glycemic control in type 2 diabetes.Nutrition, Metabolism & Cardiovascular Disease2017;1:300-306.

12. Lloyd CE, Nouwen A, Sartorius N, Ahmed HU, AlvarezA, Bahendeka S, Basangwa D, Bobrov AE, Boden S,Bulgari V, Burti L, Chaturvedi SK, Cimino LC, Gaebel W,de Girolamo G, Gondek TM, de Braude MG, GuntupalliA, Heinze MG, Ji L, Hong X, Khan A, Kiejna A, KokoszkaA, Kamala T, Lalic NM, Lecic Tosevski D, Mankovsky B,Li M, Musau A, Müssig K, Ndetei D, Rabbani G, SrikantaSS, Starostina EG, Shevchuk M, Taj R, VukovicO, Wölwer W, Xin Y. Prevalence and correlates of depressivedisorders in people with Type 2 diabetes: resultsfrom the International Prevalence and Treatmentof Diabetes and Depression (INTERPRET-DD) study, acollaborative study carried out in 14 countries. DiabetMed. 2018 Jun;35(6):760-769. doi: 10.1111/dme.13611.Epub 2018 Mar 30. PMID: 29478265.

13. Xing, S. Calip, G. The impact of depression medicationson oral antidiabetic drug adherence in patientswith diabetes and depression. Journal of Diabetesand its complications, (2017). Volumen 32. Número 12.Pag. 492-500.

14. Annisa, A. Lintang, A. Human problems: Sick role behavioramong chronic disease sufferers and varioustreatment models to increase it. Atlantis Press, (2019).Volumen 395. Número 1. Pag. 39-43.

15. Wong, E. Afshar, R. Diabetes distress, depression andglycemic control in a Canadian based specialty caresetting. Canadian Journal of Diabetes, (2017). Volumen4. Número 11. Pag. 362-365.

16. American Diabetes Association. Standards of MedicalCare in Diabetes 2018. Diab Care [Internet]. (2018)volumen 41. Número 6. Pag. 126-136. Disponibleen: http://care.diabetesjournals.org/content/suppl/2017/12/08/41.Supplement_1.DC1. [citado 9 Julio2018]

17. Yamamoto Furusho JY, Sarmiento Aguilar A, GarcíaAlanis M, Gómez García LE, Toledo Mauriño J, OlivaresGuzmán L, Fresán Orellana A. Hospital Anxiety and DepressionScale (HADS): Validation in Mexican Patientswith Inflammatory Bowel Disease. Gastroenterol Hepatol.(2018). Volumen 41. Número 8. Pag. 477-482.doi: 10.1016/j.gastrohep.2018.05.009. Epub 2018 Jun21.

18. Valero-Morenoa Selene, Lacomba-Trejoa Laura, Casaña-Granellb Sara, J. Prado-Gascóc Vicente, Montoya-Castillaa Inmaculada, Pérez-Marína Marián. Laestructura factorial de la Escala hospitalaria de Ansiedady Depresión en pacientes adolescentes con enfermedadcrónica. Arch. argent. pediatr. [Internet]. 2019Ago [citado 2023 Sep 30] ; 117( 4 ): 00-00. Disponibleen: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-00752019000400009&lng=es.